It still remains unclear to which extent the presence and the amount of retinal debris seen in internal limiting membrane (ILM) specimens harvested during macular surgery for macular holes or epiretinal membranes are related to the procedure of ILM peeling itself or to modifications of the surgical technique, such as application of vital dyes for visualization of the ILM, or to pathological conditions with epiretinal membrane formation at the vitreoretinal interface. The presence of cellular fragments on the retinal side of the removed ILM appears to be of multifactorial origin, and additional causes besides dye application need to be considered. However, morphological studies with evaluation of vital dyes are still of relevance and provide additional insights into the ultrastructure of the vitreoretinal interface and its interaction with adjuvants used during macular surgery. Chromovitrectomy is an emerging field in vitreoretinal surgery. It is of importance to better understand the tissue-dye interactions, which not only alter the mechanical properties of the tissue being stained, but may also have an impact on the functional result postoperatively.

Keywords:
Chromovitrectomy, Vitreoretinal interface, Retinal debris, Internal limiting membrane, Epiretinal membrane, Vital dye, Brilliant blue, Indocyanine green, Electron microscopy, Atomic force microscopy
1.
Brooks HL Jr: Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology 2000;107:1939-1948.
2.
Park DW, Dugel PU, Garda J, Sipperley JO, Thach A, Sneed SR, Blaisdell J: Macular pucker removal with and without internal limiting membrane peeling: pilot study. Ophthalmology 2003;110:62-64.
3.
Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S: Staining of the internal limiting membrane in macular hole surgery. Arch Ophthalmol 2000;118:1116-1118.
4.
Uemura A, Kanda S, Sakamoto Y, Kita H: Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2003;136:252-257.
5.
Tsuiki E, Fujikawa A, Miyamura N, Yamada K, Mishima K, Kitaoka T: Visual field defects after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2007;143:704-705.
6.
Baba T, Hagiwara A, Sato E, Arai M, Oshitari T, Yamamoto S: Comparison of vitrectomy with brilliant blue G or indocyanine green on retinal microstructure and function of eyes with macular hole. Ophthalmology 2012;119:2609-2615.
7.
Engelbrecht NE, Freeman J, Sternberg P Jr, Aaberg TM Jr, Aaberg TM Sr, Martin DF, Sippy BD: Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2002;133:89-94.
8.
Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, Kampik A: Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. Am J Ophthalmol 2002;134:836-841.
9.
Gandorfer A, Haritoglou C, Gass CA, Ulbig MW, Kampik A: Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. Am J Ophthalmol 2001;132:431-433.
10.
Yam HF, Kwok AK, Chan KP, Lai TY, Chu KY, Lam DS, Pang CP: Effect of indocyanine green and illumination on gene expression in human pigment epithelial cells. Invest Ophthalmol Vis Sci 2003;44:370-377.
11.
Hillenkamp J, Dydykina S, Klettner A, Treumer F, Vasold R, Bäumler W, Roider J: Safety testing of indocyanine green with different surgical light sources and the protective effect of optical filters. Retina 2010;30:1685-1691.
12.
Sato T, Ito M, Ishida M, Karasawa Y: Phototoxicity of indocyanine green under continuous fluorescent lamp illumination and its prevention by blocking red light on cultured Müller cells. Invest Ophthalmol Vis Sci 2010;51:4337-4345.
13.
Schumann RG, Gandorfer A, Priglinger SG, Kampik A, Haritoglou C: Vital dyes for macular surgery: a comparative electron microscopy study of the internal limiting membrane after macular surgery. Retina 2009;29:669-676.
14.
Eckardt C, Eckardt U, Groos S, Luciano L, Reale E: Removal of the internal limiting membrane in macular holes. Clinical and morphological findings. Ophthalmologe 1997;94:545-551.
15.
Schumann RG, Schaumberger MM, Rohleder M, Haritoglou C, Kampik A, Gandorfer A: Ultrastructure of the vitreomacular interface in full-thickness idiopathic macular holes: a consecutive analysis of 100 cases. Am J Ophthalmol 2006;141:1112-1119.
16.
Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C: An in-vivo evaluation of brilliant blue G in animals and humans. Br J Ophthalmol 2008;92:1142-1147.
17.
Haritoglou C, Schumann R, Reiniger I, Rohleder M, Priglinger SG, Kampik A, Gandorfer A: Evaluation of the ILM after conventional peeling during macular hole surgery. Retina 2006;26:21-24.
18.
Kenawy N, Wong D, Stappler T, Romano MR, Das RA, Hebbar G, Prime W, Heimann H, Gibran SK, Sheridan CM, Cheung YH, Hiscott PS: Does the presence of an epiretinal membrane alter the cleavage plane during internal limiting membrane peeling? Ophthalmology 2010;117:320-323.
19.
Eagle RC: Wills Eye Hospital; in Rapuano CJ (ed): Year Book of Ophthalmology. St Louis, Mosby, 2003, pp 276-278.
20.
Schumann RG, Yang Y, Haritoglou C, Schaumberger MM, Eibl KH, Kampik A, Gandorfer A: Histopathology of internal limiting membrane peeling in traction induced maculopathies. J Clin Exp Ophthalmol 2012;3:4-10.
21.
Bringmann A, Wiedemann P: Involvement of Müller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol 2009;247:865-883.
22.
Lindqvist N, Liu Q, Zajadacz J, Franze K, Reichenbach A: Retinal glial (Müller) cells: sensing and responding to tissue stretch. Invest Ophthalmol Vis Sci 2010;51:1683-1690.
23.
Haritoglou C, Schumann RG, Kampik A, Gandorfer A: Glial cell proliferation under the internal limiting membrane in a patient with cellophane maculopathy. Arch Ophthalmol 2007;125:1301-1302.
24.
Wolter RJ: Pores in the inner limiting membrane of the human retina. Acta Ophthalmol 1964;42:971.
25.
Roth AM, Foos RY: Surface structure of the optic nerve head. 1. Epipapillary membranes. Am J Ophthalmol 1972;74:977-985.
26.
Rentsch FJ: The ultrastructure of preretinal macular fibrosis. Graefes Arch Clin Exp Ophthalmol 1977;203:321-337.
27.
Kampik A, Kenyon KR, Michels RG, Green WR, de la Cruz ZC: Epiretinal and vitreous membranes. Comparative study of 56 cases. Arch Ophthalmol 1981;99:1445-1454.
28.
Gandorfer A, Schumann R, Scheler R, Haritoglou C, Kampik A: Pores of the inner limiting membrane in flat-mounted surgical specimens. Retina 2011;31:977-981.
29.
Streeten BA: Disorders of the vitreous; in Garner A, Klintworth GK (eds): Pathophysiology of Ocular Disease - A Dynamic Approach, Part B. New York, Dekker, 1982, pp 1381-1419.
30.
Halfter W, Dong S, Dong A, Eller AW, Nischt R: Origin and turnover of ECM proteins from the inner limiting membrane and vitreous body. Eye 2008;22:1207-1213.
31.
Candiello J, Balasubramani M, Schreiber EM, Cole GJ, Mayer U, Halfter W, Lin H: Biomechanical properties of native basement membranes. FEBS J 2007;274:2897-2908.
32.
Henrich PB, Monnier CA, Halfter W, Haritoglou C, Strauss RW, Lim RY, Loparic M: Nanoscale topographic and biomechanical studies of the human internal limiting membrane. Invest Ophthalmol Vis Sci 2012;53:2561-2570.
33.
Wollensak G, Spoerl E, Wirbelauer C, Pham DT: Influence of indocyanine green staining on the biomechanical strength of porcine internal limiting membrane. Ophthalmologica 2004;218:278-282.
34.
Wollensak G: Biomechanical changes of the internal limiting membrane after indocyanine green staining. Dev Ophthalmol 2008;42:82-90.
35.
Foote CS: Definition of type I and type II photosensitized oxidation. Photochem Photobiol 1991;54:659.
36.
Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, Kampik A: The effect of indocyanine-green on functional outcome of macular pucker surgery. Am J Ophthalmol 2003;135:328-337.
37.
Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T: Morphological and functional damage of the retina caused by intravitreous indocyanine green rat eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:209-213.
38.
Gandorfer A, Haritoglou C, Gandorfer A, Kampik A: Retinal damage from indocyanine green in experimental macular surgery. Invest Ophthalmol Vis Sci 2003;44:316-323.
39.
Sippy BD, Engelbrecht NE, Hubbard GB, Moriarty SE, Jiang S, Aaberg TM Jr, Aaberg TM Sr, Grossniklaus HE, Sternberg P: Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. Am J Ophthalmol 2001;132:433-435.
40.
Stalmans P, Van Aken EH, Veckeneer M, Feron EJ, Stalmans I: Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am J Ophthalmol 2002;134:282-285.
41.
Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lueke M, Bartz-Schmidt KU, Grisanti S: Systemic evaluation of ICG and trypan blue related effects on ARPE-19 cells in vitro. Exp Eye Res 2007;85:880-889.
42.
Rodrigues EB, Penha FM, Farah ME, de Paula Fiod Costa E, Maia M, Dib E, Bottós J, Freymuller E, Furlani B, Meyer CH, Magalhães O Jr, Lima-Filho AA, Safatle A: Preclinical investigation of the retinal biocompatibility of six novel vital dyes for chromovitrectomy. Retina 2009;29:497-510.
43.
Mackenzie SE, Gandorfer A, Rohleder M, Schumann R, Schlottmann PG, Bunce C, Xing W, Gregor Z, Charteris DG: Ultrastructure and retinal imaging of internal limiting membrane: a clinicopathologic correlation of trypan blue stain in macular hole surgery. Retina 2010;30:655-661.
44.
Mackenzie SE, Gandorfer A, Rohleder M, Schumann R, Schlottmann PG, Bunce C, Xing W, Gregor Z, Charteris DG: Ultrastructure and retinal imaging of epiretinal membrane: a clinicopathologic correlation of trypan blue staining in epiretinal membrane surgery. Retina 2010;30:648-654.
45.
Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T: Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 2006;26:631-636.
46.
Ueno A, Hisatomi T, Enaida H: Biocompatibility of brilliant blue G in a rat model of subretinal injection. Retina 2007;27:499-504.
47.
Januschowski K, Mueller S, Spitzer MS, Schramm C, Doycheva D, Bartz-Schmidt KU, Szurman P: Evaluating retinal toxicity of a new heavy intraocular dye, using a model of perfused and isolated retinal cultures of bovine and human origin. Graefes Arch Clin Exp Ophthalmol 2012;250:1013-1022.
48.
Rodrigues EB, Meyer CH, Mennel S, Farah ME: Mechanisms of intravitreal toxicity of indocyanine green dye: implications for chromovitrectomy. Retina 2007;27:958-970.
49.
Schumann RG, Remy M, Grueterich M, Gandorfer A, Haritoglou C: How it appears: electron microscopic evaluation of internal limiting membrane specimens obtained during brilliant blue G assisted macular hole surgery. Br J Ophthalmol 2008;92:330-331.
50.
Farah ME, Maia M, Rodrigues EB: Dyes in ocular surgery: principles for use in chromovitrectomy. Am J Ophthalmol 2009;148:332-340.
51.
Gass CA, Haritoglou C, Schaumberger M, Kampik A: Functional outcome of macular hole surgery with and without indocyanine-green assisted internal limiting membrane peeling. Graefes Arch Clin Exp Ophthalmol 2003;241:716-720.
52.
Sivalingam A, Eagle RC Jr, Duker JS, Brown GC, Benson WE, Annesley WH Jr, Federman J: Visual prognosis correlated with the presence of internal-limiting membrane in histopathologic specimens obtained from epiretinal membrane surgery. Ophthalmology 1990;97:1549-1552.
53.
Terasaki H, Mijake Y, Nomura R, Piao CH, Hori K, Niwa T, Kondo M: Focal macular ERGs in eyes after removal of macular ILM during macular hole surgery. Invest Ophthalmol Vis Sci 2001;42:229-234.
54.
Tadayoni R, Paques M, Massin P, Mouki-Benani S, Mikol J, Gaudric A: Dissociated optic nerve fiber layer appearance of the fundus after idiopathic epiretinal membrane removal. Ophthalmology 2001;108:2279-2283.
55.
Ito Y, Terasaki H, Takahashi A, Yamakoshi T, Kondo M, Nakamura M: Dissociated optic nerve fiber layer appearance after internal limiting membrane peeling for idiopathic macular holes. Ophthalmology 2005;112:1415-1420.
56.
Mitamura Y, Ohtsuka K: Relationship of dissociated optic nerve fiber layer appearance to internal limiting membrane peeling. Ophthalmology 2005;112:1766-1770.
57.
Haritoglou C, Ehrt O, Gass CA, Kristin N, Kampik A: Paracentral scotomata: a new finding after vitrectomy for idiopathic macular hole. Br J Ophthalmol 2001;85:231-233.
58.
Kim CY, Lee JH, Lee SJ, Koh HJ, Lee SC, Kwon OW: Visual field defect caused by nerve fiber layer damage associated with an internal limiting lamina defect after uneventful epiretinal membrane surgery. Am J Ophthalmol 2002;133:569-571.
59.
Lim JW, Kim HK, Cho DY: Macular function and ultrastructure of the internal limiting membrane removed during surgery for idiopathic epiretinal membrane. Clin Exp Ophthalmol 2011;39:9-14.
60.
Tari SR, Vidne-Hay O, Greenstein VC, Barile GR, Hood DC, Chang S: Functional and structural measurements for the assessment of internal limiting membrane peeling in idiopathic macular pucker. Retina 2003;27:567-572.
61.
Christensen UC, Kroyer K, Sander B, Larsen M, Henning V, Villumsen J, la Cour M: Value of internal limiting membrane peeling in surgery for macular hole stage 2 and 3: a randomized clinical trial. Br J Ophthalmol 2009;93:1005-1015.
62.
Alkabes M, Salinas C, Vitale L, Burés-Jelstrup A, Nucci P, Mateo C: En face optical coherence tomography of inner retinal defects after internal limiting membrane peeling for idiopathic macular hole. Invest Ophthalmol Vis Sci 2011;52:8349-8355.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.